The BioInsights Podcast
The BioInsights Podcast: discussing the challenges of translating novel biologics from bench to clinic to market.
The BioInsights Podcast
Driving innovation in cell and gene therapy: the role of AI and robotics
•
BioInsights
•
Season 3
•
Episode 12
Use Left/Right to seek, Home/End to jump to start or end. Hold shift to jump forward or backward.
Jokūbas Leikauskas, Editor, Cell & Gene Therapy Insights, speaks with OmniaBio Inc.’s Kenneth Harris, Chief Strategy Officer and Head of AI, Mitchel Sivilotti, President and CEO, and Anthony Rotunno, Senior Vice President and General Manager/Site Head, about the innovative advancements in cell and gene therapy, focusing on how AI, automation, and robotics are revolutionizing manufacturing processes by reducing costs, increasing production capacity, and ultimately, improving patient outcomes in the rapidly evolving cell and gene therapy field.
What makes CGT a pivotal advancement in the evolution of modern medicine, and how do you envision this field evolving in the coming years?
What is the main mission of OmniaBio?
What sets OmniaBio apart in the field of CGT manufacturing?
How are you implementing AI and robotics to improve CGT manufacturing?
What are the challenges and concerns regarding AI and how are you planning to address them?
What excites you the most about the future of OmniaBio in the context of the rapidly evolving CGT industry?